

Cancer Clinical Trials

Study with investigational drug PF-06463922 and comparator crizotinib in patients with a specific type of advanced lung cancer



📅 24/May/2017 ⌚ Ongoing 🏥 Unknown 📋 EU Clinical Trials Register

- To demonstrate that lorlatinib as a single agent (Arm A) is superior to crizotinib alone (Arm B) in prolonging progression-free survival (PFS) in advanced ALK-positive NSCLC patients who are...

Conditions: ◦ Advanced ALK positive non small cell lung cancer

Interventions: ◦ PF-06463922
◦ Xalkori (crizotinib)

2.1GB SQL dump
350,000 trials



Summary Analysis

24,000
cancer
trials
entries

TF-IDF
vectorizer
Top 1000
words

Kmean
Clustering
15 centers

brief_summary

RATIONALE: Opioids lessen pain caused by cancer. Titration of opioids in the hospice set...

RATIONALE: Studying the genes expressed in samples of blood from patients with cancer a...

RATIONALE: Photodynamic therapy uses a drug that becomes active when it is exposed...

Platinum Retreated in Patients with Platinum Sensitive mTNBC

NULL

This project has been completed and consisted of a randomised trial of six tailored...


Patients with advanced or metastatic (stage IIIB-IV) non small cell lung cancer who have...

In this research study, the investigators are trying to determine if there are measurable ...

Overall response rate in the study population;
objective response rate in the KRAS wild typ...




The primary objectives are:

The goal of this clinical research study is to see if the drug OROS Methylphenidate HCl ...






and


[illegible]

Predicting trial failure


KNN (K=10)




Boosted trees




RUSboosted trees




Model 2



Model 4



Model 3



For researchers

Mertrazine and Cobazol to Treat Major Depression


 XML



[OpenTrials](#) > [For Researchers](#) > [Depression](#) > [Mertrazine and Cobazol](#)


Overview

Condition: Major Depression

Treatment:  Mertrazine,  Cobazol

 June 2004 - March 2010

218 Participants

 Men and women

Aged 18-65

Registries

[ClinicalTrials.gov](#) 


[BioMet Inc](#) 

 Add another


Papers

[Results paper](#) 


[Protocol paper](#) 

 Add another

Regulatory documents

[CSR](#) 

[EPAR segment](#) 

 Add another

Structured data

[ClinicalTrials.gov results](#) 

[SRDR from AHRQ](#) 

 Add another


Paperwork


[Blank consent form](#) 

[Patient information sheet](#) 


[Blank case report form](#) 

[Protocol](#) 

[Statistical analysis plan](#) 

[Lay summary](#) 

[Ethics/IRB Approval](#) 

 Add another

Methodological rigour


Conducted in
Maryland, USA




Colorectal Cancer

- 3rd most common cancer in men and women in US
- 2nd leading cause of cancer death for men and women combined
- 5 year relative survival rate at time of diagnosis
 - 90% survival when diagnosed at stage I
 - 11% survival when diagnosed at stage IV (metastatic)
 - Only 40% of patients are diagnosed at stage I
- Enhanced screening efforts (guaiac-based fecal occult blood test – gFOBT – and colonoscopies) have led to decreased overall mortality rates in CRC, but 45% of population is not compliant with current screening guidelines
 - More user friendly screening platforms are required to enhance patient compliance with screening guidelines

Liquid Biopsies




OpenTrials API




Initial Data Exploration


Colorectal cancer trials per year




Min Age



Fraction of total trials by country



Max Age



```
graph LR; A[24,000 trials entries] --> B[TF-IDF vectorize<br/>Top 1000 words]; B --> C[Kmean Clustering<br/>15 centers]
```

24,000 trials entries

TF-IDF
vectorize
Top 1000 words

Kmean
Clustering
15 centers



Colorectal AND Bevacizumab

